Fig 2: Blockade of the CD93-IGFBP7 axis inhibits tumor progression in RIP1-Tag2 mice(A–F) Ten-week-old male RIP1-Tag2 mice were randomized into either anti-CD93 mAb treatment or control group. (A) Schema of experiment. (B) Blood glucose was recorded every other day (n = 8–10, error bars are SEM). (C) Mouse survival was monitored over time (Log-rank Mantel-Cox test, n = 17–18). (D and E) After 2 weeks of antibody treatment, pancreatic tissues were harvested for analysis. (D) H&E staining of pancreas tissues was performed to identify tumors (arrowhead). Tumor area and counts were quantified (unpaired t tests, n = 5). (E) Pancreatic tissues were stained for CD31 (red) and ⍺SMA (white) to assess mature blood vessels (unpaired t test, n = 5). (F) Cancer cells in peripancreatic LNs were detected and quantified by staining for SV40 Tag (unpaired t test, n = 4). (G and H) Ten-week-old female RIP1-Tag2 mice were treated with control or anti-IGFBP7 mAb. (G) Schema of experiment. (H) Mouse survival was monitored over time. (Log-rank Mantel-Cox test, n = 8–9). MS, median survival.